Overview
International law firm McDermott Will & Emery represented Claris Ventures SGR in its equity investment in a EUR 10 million seed round in Resalis Theraputics, a biotech startup whose transformative metabolic disease approach targets a master regulator of multiple pathways underlying obesity and fatty liver disease.
Resalis Therapeutics is a scale-up operating in Italy. The funding will support the finalization of IND-enabling studies for the company’s lead program, RES-010, which Resalis will initially develop as a novel treatment for obesity and nonalcoholic fatty liver disease (NAFLD).
Claris Ventures, through its funds “Claris Biotech I” and “Claris Biotech I – Parallel Fund”, was the lead investor of the round, backed by Italian Angels for Growth and Club degli Investitori.
McDermott Will & Emery Studio Legale Associato assisted Claris Ventures in all legal aspects of the transaction, with partners Ettore Scandale and Fabrizio Faina (first closing) and associate Stefano Pardini, supported by trainee Matteo Landini (second closing).
About McDermott
McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.
